Hjem › Brystkreft › Indiana › Indianapolis
Kliniske studier for Brystkreft i Indianapolis, IN
20 studier for Brystkreft søker deltakere på steder i og rundt Indianapolis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruttererFase 3
- Community Health Network, Inc, Indianapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruttererFase 3
- Investigative Clinical R of Indiana, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RekruttererFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekruttererFase 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutterer
- Indiana University, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Indiana University (IU) School of Medicine, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruttererFase 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruttererFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekruttererFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruttererFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- og 5 flere
HER2 Vaccine for Locally Advanced Breast Cancer
RekruttererFase 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Rekrutterer
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruttererFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi unna
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RekruttererFase 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RekruttererFase 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Rekrutterer
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruttererFase 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · 16 mi unna
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruttererFase 1
- Community Health Network, Indianapolis
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Indianapolis
- Ikke-småcellet lungekreft32 studier
- Kreft (alle typer)24 studier
- Hjertesvikt23 studier
- Fedme20 studier
- Metastatisk kreft19 studier
- Kolorektal kreft18 studier
- Eggstokkreft17 studier
- Kardiovaskulær sykdom17 studier
- Lungekreft16 studier
- Type 1-diabetes14 studier
- Endometriekreft14 studier
- Alzheimers sykdom14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.